WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012104836) SNX9 AS A NOVEL BIOMARKER FOR CHRONIC INFLAMMATION AND ASSOCIATED IMMUNOSUPPRESSION AND A NEW REGULATOR OF T CELL RECEPTOR EXPRESSION AND FUNCTION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/104836    International Application No.:    PCT/IL2012/000053
Publication Date: 09.08.2012 International Filing Date: 31.01.2012
IPC:
G01N 33/564 (2006.01), G01N 33/569 (2006.01), G01N 33/574 (2006.01)
Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. [IL/IL]; Hi Tech Park Edmond J. Saffra Campus Givat Ram P.O.B. 39135 91390 Jerusalem (IL) (For All Designated States Except US).
BANIYASH, Michal [IL/IL]; (IL) (For US Only).
ISH SHALOM, Eliran [IL/IL]; (IL) (For US Only)
Inventors: BANIYASH, Michal; (IL).
ISH SHALOM, Eliran; (IL)
Agent: REINHOLD COHN AND PARTNERS; P.O.B 13239 61131 Tel Aviv (IL)
Priority Data:
61/437,952 31.01.2011 US
Title (EN) SNX9 AS A NOVEL BIOMARKER FOR CHRONIC INFLAMMATION AND ASSOCIATED IMMUNOSUPPRESSION AND A NEW REGULATOR OF T CELL RECEPTOR EXPRESSION AND FUNCTION
(FR) SNX9 EN TANT QUE NOUVEAU BIOMARQUEUR POUR L'INFLAMMATION CHRONIQUE ET L'IMMUNOSUPPRESSION ASSOCIÉE ET NOUVEAU RÉGULATEUR DE L'EXPRESSION DES RÉCEPTEURS DE CELLULES T ET FONCTION
Abstract: front page image
(EN)The present invention relates to diagnostic and prognostic methods and kits for assessing chronic inflammation and associated immune-suppression. More particularly, the invention relates to the use of SNX9 (sorting nexin 9 protein) as a biomarker for chronic inflammation and associated immune-suppression, specifically, in subjects suffering from chronic inflammatory conditions. The invention further provides a prognostic tool for detecting regression or recurrence of the diseases and a powerful tool for assessing efficacy of a treatment. The present invention further provides SNX9 as an immunomodulator and therefore relates to methods for treating immune-related disorders by modulating SNX9 expression.
(FR)La présente invention concerne des procédés et des kits de diagnostic et de pronostic permettant d'évaluer l'inflammation chronique et l'immunosuppression associée. Plus précisément, l'invention concerne l'utilisation de la SNX9 (protéine Sorting Nexin 9) en tant que biomarqueur de l'inflammation chronique et de l'immunosuppression associée, notamment chez des sujets souffrant de pathologies inflammatoires chroniques. L'invention concerne en outre un outil de pronostic permettant de détecter la régression ou la récurrence des maladies et un outil puissant permettant d'évaluer l'efficacité d'un traitement. La présente invention a en outre trait à la SNX9 en tant qu'immuno-modulateur et concerne par conséquent des procédés de traitement de troubles de type immunitaire en modulant l'expression de la SNX9.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)